journal article·2017-11-17Open access

A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles’ characteristics and efficacy of intracellular delivery

Adem Sahin, Gunes Esendagli, Firat Yerlikaya, Secil Caban-Toktas, Digdem Yoyen-Ermis, Utku Horzum, Yesim Aktas, Mansoor Khan, Patrick Couvreur, Yilmaz Capan

Abstract

In this study, it was aimed to investigate characteristics and intracellular delivery of two different-sized PLGA nanoparticles in ouzo region by considering number of nanoparticles. To determine the effect of formulation parameters on average particle size, Dil labeled nanoparticles were prepared using a three-factor, two-level full factorial statistical experimental design. PLGA230 (230.8 ± 4.32 nm) and PLGA160 (157.9 ± 6.16 nm) nanoparticles were obtained by altering polymer amount based on experimental design results and characterized. Same number of PLGA230 and PLGA160 nanoparticles per cell were applied onto HEK293 cells; then, cytotoxicity, uptake kinetics and mechanism were evaluated by flow cytometry and fluorescent microscopy. Also same weight of PLGA230 and PLGA160 nanoparticles were applied and cellular uptake of these nanoparticles was evaluated. It was found that PLGA230 nanoparticles had higher encapsulation efficiency and slower dye release compared to PLGA160 nanoparticles. When they were applied at same counts per cell, PLGA230 nanoparticles displayed faster and higher intracellular dye transfer than PLGA160 nanoparticles. On the other hand, PLGA160 appeared to be a more effective vehicle than PLGA230 when applied at the same weight concentration. It was also shown that for both nanoparticles, HEK293 cells employed macropinocytic, caveolae- and clathrin-mediated endocytic pathways.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey;

Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey;

Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey;

Elixir Pharmaceutical Research and Development Corporation, Ankara, Turkey;

Irma Lerma Rangel College of Pharmacy, Texas A&M University, TX, USA;

Institut Galien Paris-Sud UMR CNRS 8612, Faculty of Pharmacy, University Paris-Sud XI, Châtenay-Malabry, France

References (45)

Show source-provided references
1. 10.1016/j.ijpharm.2015.08.05010.1016/j.ijpharm.2015.08.050 ↗
2. 10.1073/pnas.130500011010.1073/pnas.1305000110 ↗
3. 10.1002/cyto.a.2222810.1002/cyto.a.22228 ↗
4. 10.1081/DDC-10010219710.1081/DDC-100102197 ↗
5. 10.1039/C5NR01695A10.1039/C5NR01695A ↗
6. 10.1016/j.ejps.2010.06.00710.1016/j.ejps.2010.06.007 ↗
7. 10.1038/mtm.2014.5810.1038/mtm.2014.58 ↗
8. 10.1016/j.ijpharm.2009.04.03510.1016/j.ijpharm.2009.04.035 ↗
9. 10.1007/s11095-011-0624-110.1007/s11095-011-0624-1 ↗
10. 10.1038/nnano.2011.5810.1038/nnano.2011.58 ↗
11. 10.1016/j.jconrel.2012.01.04310.1016/j.jconrel.2012.01.043 ↗
12. 10.1021/acs.jpcc.5b0211110.1021/acs.jpcc.5b02111 ↗
13. 10.4161/cl.2396710.4161/cl.23967 ↗
14. 10.1016/j.jconrel.2006.02.01610.1016/j.jconrel.2006.02.016 ↗
15. 10.1038/nnano.2014.27410.1038/nnano.2014.274 ↗
16. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
17. 10.1007/s00018-009-0053-z10.1007/s00018-009-0053-z ↗
18. 10.1083/jcb.20090808610.1083/jcb.200908086 ↗
19. 10.1016/j.addr.2013.12.00910.1016/j.addr.2013.12.009 ↗
20. 10.1039/C3NR06371B10.1039/C3NR06371B ↗
21. 10.3390/polym303137710.3390/polym3031377 ↗
22. 10.1016/j.tiv.2014.12.02110.1016/j.tiv.2014.12.021 ↗
23. 10.3109/21691401.2016.116371410.3109/21691401.2016.1163714 ↗
24. 10.1016/j.cis.2011.02.00510.1016/j.cis.2011.02.005 ↗
25. 10.1038/mt.2008.12710.1038/mt.2008.127 ↗
26. 10.1002/smll.20080046110.1002/smll.200800461 ↗
27. 10.1016/S0169-409X(02)00228-410.1016/S0169-409X(02)00228-4 ↗
28. 10.3109/21691401.2014.91305410.3109/21691401.2014.913054 ↗
29. 10.1023/B:PHAM.0000022411.47059.7610.1023/B:PHAM.0000022411.47059.76 ↗
30. 10.1080/21691401.2016.119645710.1080/21691401.2016.1196457 ↗
31. 10.1002/smll.20150339610.1002/smll.201503396 ↗
32. 10.1042/bj2003125310.1042/bj20031253 ↗
33. 10.1016/j.ijpharm.2014.01.01410.1016/j.ijpharm.2014.01.014 ↗
34. 10.1155/2015/79460110.1155/2015/794601 ↗
35. 10.1016/j.jconrel.2010.01.03610.1016/j.jconrel.2010.01.036 ↗
36. 10.1016/S0168-3659(02)00127-X10.1016/S0168-3659(02)00127-X ↗
37. 10.1039/C0SM00862A10.1039/C0SM00862A ↗
38. 10.1039/C4CS00128A10.1039/C4CS00128A ↗
39. 10.1101/SQB.1995.060.01.02810.1101/SQB.1995.060.01.028 ↗
40. 10.1002/cyto.a.2285310.1002/cyto.a.22853 ↗
41. 10.1002/aic.69005042110.1002/aic.690050421 ↗
42. 10.1038/srep1009110.1038/srep10091 ↗
43. 10.1083/jcb.123.5.110710.1083/jcb.123.5.1107 ↗
44. 10.1016/j.biomaterials.2004.07.05010.1016/j.biomaterials.2004.07.050 ↗
45. 10.1016/j.jconrel.2014.06.03810.1016/j.jconrel.2014.06.038 ↗